Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your not very nice
He's someone that shouldn't be trading.
Well im worried because 6-4 is coming and i dont see it coming
Cause it makes you sound like some old dude in the nursing home with short term memory loss.
Guess that could be one explanation…
You ask about the split like every day lol
Isnt the 1:175 reduction a rs pretty much?
The merger supposed to happen by 6-4? Cant the dr pull the bigger rs
John Zidar
@JohnZidar
$WENA Put no faith in my numbers...I have limited info. I was working with basic math. I may be close...but who really knows ...and for the Record it is 1:175, a reduction.
anyone have a clue on what the RS will be? 1:2500??
+>>>>LEAS - yea like WTF is going on... had 10k in this and now it looks like a couple hundred bucks. LMFAO
Patiently waiting whatever the case
Weeeeeeeeeee
CC
is this shit gunna happen?
I think this can be traded in Canada.
Honestly what kind of rs is likely to happen here?
Dude all im asking is if the 170k os is bullish
You should not be trading, it's too much for you to handle.
U talking to me?
sorry but you should not be trading :o)
how is that good??
*Rwod share outstanding updated 170,420.01
https://www.cnbc.com/quotes/RWOD
"As of May 8, 2024, RWOD has received requests to redeem a total of 1,589,776 RWOD Shares. As of May 8, 2024, the pro rata portion of the Trust Account each public share would be entitled to receive upon redemption (the “Redemption Price”) is approximately $11.20 per share (prior to the deduction of any applicable taxes). Stockholders who wish to withdraw their previously submitted redemption requests may do so by requesting RWOD’s transfer agent, Continental Stock Transfer & Trust Company, to return such shares. Based on the redemption requests received as of the date hereof, RWOD will have a total of 170,418 RWOD Shares outstanding following redemptions."
Face it, you have been flocked (like a Christmas tree)!
Dont they have to say if deal feel through?
Don’t know, but I have a bunch I got cheap so I’ll just wait and see like everybody else.
Isnt this a bad sign they have not filed yet?
Seriously tho oceans do you think will get this closed soon??
Hey oceans when do u think this closes?
So why did you buy?
Are you some sort of weird scam follower?
LEAS shareholders have been plucked (like a chicken) big time! That’s what happens when you buy into a scam’
U still think will come out ahead when this does close? What conversion do you see happening?
Oh- all those super- reliable Stocktwits people.
I rely on them for all my financial advice.
Yeah, right….
LMAO
On stock twits… by looking at the pr over the weekend
Got any names of who thinks that?
And don’t throw out your dog’s name, LOL
Some think will get .0002 after all set and done :(
So what r u saying??
All in the s4 pretaining to reverse split the last updated s4 on February 13, 2024 lead to Shareholders voted on April 12, 2024
News incoming that's the only reasons for this mindless talk about reverse split.
FoLKS LOCKED OUT OF This Merger .. $WENA NEXT
"NO LONGER BE Necessary "
Keywords
"Contemplated" January 4, 2022
"not been declared effective" September 30, 2023
"a reverse split will no longer be necessary as the combined company will be renamed ANEW MEDICAL Inc. " February 13, 2024
"The Company’s pending name change to ANEW MEDICAL Inc. and on the Business Combination closing date and the Company’s outstanding common stock and preferred stock will be converted into 6,000,000 shares of the combined company’s common stock."
"On November 1, 2021, the shareholders of the Company approved a name change to ANEW Medical, Inc. and approved a 1-for-2500 reverse split.
On January 4, 2022, the Company filed an Articles of Amendment with the State of Wyoming, changing its name to “ANEW Medical, Inc.” and the contemplated 1-for-2,500 reverse split. During January 2022 and in accordance with SEC Rule 10b-17 and FINRA Rule 6490, the Company submitted documents and other information to FINRA in furtherance of pursuing and obtaining approval of the subject reverse stock split and name change. The Company must submit the additional documents requested by, and necessary to obtain approval of, FINRA in connection with the subject reverse stock split and name change. As of September 30, 2023, the reverse split and name change have not been declared effective by FINRA to broker deals in the quotation system."
you two are really the biggest losers just hangin out on this board. :o)
WRONG. THE RS NO LONGER NEEDED STATEMENT IS GOING TO GET HIM IF HE DECIDES TO BE FUNNY.
Not a chance. He told everyone about it way up front, those that chose to ignore it are on their own. He’s free and clear.
If you really believe you’re going to get something out of your $LEAS shares…you’re going to be very disappointed!
YOU AND THE DOC CAN DREAM ABOUT ALL YOU WANT BUT AT THE END OF THE DAY THERE IS NOTHING HE CAN DO. OTHERWISE HE WILL END UP IN JAIL, LOL
Yes, I did. Know what else? That was because he knew it was simple to do the math while distributing the RWOD shares. The RS is in the corporate charter and well advertised. Only thing left was for FINRA to process it, but since the LEAS shares were going away, he didn't need them to.
We've had this conversation before a couple times, and it always ends with this: The owners of ANEW had 100% of its equity before the RM (including the CEO who owned about 30% of it). Now, do you really believe they were going to share it with the bagholders of over 1B LEAS shares for nothing?
trader sounds like a bear
Did you read the company publicly announced that RS is no longer needed? And that's in the SEC filings.
Dr. Sinkule has control of the vote for LEAS. He can do whatever he wants, including implementing the RS that he told everybody about over and over again and put into effect with a corporate charter amendment to the state of Wyoming. He’s going to do the math that will divide those 1.04B shares of LEAS common stock by the 2500 - 1 RS ratio, then he’s going to do more math to convert those 405k preferred shares into 40.5M common shares, then he’s going to distribute the RWOD shares on that basis. Dr. Sinkule is no dummy. He owned 30% of ANEW all by himself, and he’s not going to let the bagholders of LEAS cheat him out of his stake in his own company.
If anyone had taken the time to read through the documents published by LEAS from the point the RM happened, they’d know the intent from the outset was to RS and wipe out the old bags, then the preferred shareholders would convert and hold the vast majority of the O/S just like they held the equity in ANEW.
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |